We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is J&J's MedTech Segment Set for Another Quarter of Growth?
Read MoreHide Full Article
Key Takeaways
Q3 MedTech growth at J&J should have been driven by strength in Cardiovascular and Surgery.
New products and acquired units, Abiomed and Shockwave, are expected to have fueled further sales momentum.
VBP impacts in China might have restrained J&J's MedTech profit performance in Q3.
Johnson & Johnson's (JNJ - Free Report) medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J’s total revenues.
In the MedTech segment, though issues in Asia Pacific markets, specifically China, are hurting sales, J&J is successfully shifting its portfolio to high innovation, high growth markets, particularly in Cardiovascular. With the acquisitions of Shockwave in 2024 and Abiomed in 2022, J&J has become a category leader in four of the largest and highest-growth cardiovascular intervention MedTech markets. Sales in its Cardiovascular segment rose 20% in the first half of 2025.
Second-quarter sales in J&J’s MedTech segment improved from first-quarter levels, driven by the newly acquired cardiovascular businesses, Abiomed and Shockwave, as well as growth in Surgical Vision and wound closure within the Surgery division. The MedTech segment is expected to have continued to witness strong momentum in Cardiovascular, Surgery and Vision in the third quarter, backed by increased adoption of newly launched products.
However, the MedTech business continues to face headwinds in the Asia Pacific, particularly in China, where sales are being hurt by the impact of the volume-based procurement (VBP) program. VBP is a government-driven cost containment effort in China.
J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. It expects continued impacts from VBP issues in the country this year as the program continues to expand across provinces and products. Competitive pressure is also hurting sales growth in some MedTech businesses like energy and endocutters in Surgery.
Nonetheless, MedTech sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum. However, tariff-related costs are expected to hurt profits in the MedTech segment.
Our estimates for the MedTech unit suggest a CAGR of around 4.6% over the next three years.
J&J’s Key Competitors in the Medical Devices Market
J&J’s MedTech unit faces strong competition from several major players in the medical device industry like Medtronic (MDT - Free Report) , Abbott, Stryker (SYK - Free Report) and Boston Scientific (BSX - Free Report) .
While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry year to date. The stock has risen 31.9% in the year-to-date period compared with a 6.4% increase in the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 16.93 forward earnings, higher than 15.70 for the industry. The stock is also trading above its five-year mean of 15.64.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.86 per share, while that for 2026 has risen from $11.36 to $11.38 over the past 60 days.
Image: Bigstock
Is J&J's MedTech Segment Set for Another Quarter of Growth?
Key Takeaways
Johnson & Johnson's (JNJ - Free Report) medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech segment accounts for around 36% of J&J’s total revenues.
In the MedTech segment, though issues in Asia Pacific markets, specifically China, are hurting sales, J&J is successfully shifting its portfolio to high innovation, high growth markets, particularly in Cardiovascular. With the acquisitions of Shockwave in 2024 and Abiomed in 2022, J&J has become a category leader in four of the largest and highest-growth cardiovascular intervention MedTech markets. Sales in its Cardiovascular segment rose 20% in the first half of 2025.
Second-quarter sales in J&J’s MedTech segment improved from first-quarter levels, driven by the newly acquired cardiovascular businesses, Abiomed and Shockwave, as well as growth in Surgical Vision and wound closure within the Surgery division. The MedTech segment is expected to have continued to witness strong momentum in Cardiovascular, Surgery and Vision in the third quarter, backed by increased adoption of newly launched products.
However, the MedTech business continues to face headwinds in the Asia Pacific, particularly in China, where sales are being hurt by the impact of the volume-based procurement (VBP) program. VBP is a government-driven cost containment effort in China.
J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. It expects continued impacts from VBP issues in the country this year as the program continues to expand across provinces and products. Competitive pressure is also hurting sales growth in some MedTech businesses like energy and endocutters in Surgery.
Nonetheless, MedTech sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum. However, tariff-related costs are expected to hurt profits in the MedTech segment.
Our estimates for the MedTech unit suggest a CAGR of around 4.6% over the next three years.
J&J’s Key Competitors in the Medical Devices Market
J&J’s MedTech unit faces strong competition from several major players in the medical device industry like Medtronic (MDT - Free Report) , Abbott, Stryker (SYK - Free Report) and Boston Scientific (BSX - Free Report) .
While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care.
JNJ’s Price Performance, Valuation and Estimates
J&J’s shares have outperformed the industry year to date. The stock has risen 31.9% in the year-to-date period compared with a 6.4% increase in the industry.
From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 16.93 forward earnings, higher than 15.70 for the industry. The stock is also trading above its five-year mean of 15.64.
The Zacks Consensus Estimate for 2025 earnings has remained unchanged at $10.86 per share, while that for 2026 has risen from $11.36 to $11.38 over the past 60 days.
J&J has a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.